Exelixis Inc Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Exelixis Inc (EXEL) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of $75.55 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-22.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2012-02-22
- Exelixis Inc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2011 was $75.55M.
- Exelixis Inc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2010 was -$92.47M.
- Exelixis Inc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2009 was -$139.40M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2011-12-31 | $75.55M 10-K · filed 2012-02-22 |
| 2010-12-31 | -$92.47M 10-K · filed 2012-02-22 |
| 2009-12-31 | -$139.40M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |